[go: up one dir, main page]

FI961350L - Hapten-märkta peptider - Google Patents

Hapten-märkta peptider Download PDF

Info

Publication number
FI961350L
FI961350L FI961350A FI961350A FI961350L FI 961350 L FI961350 L FI 961350L FI 961350 A FI961350 A FI 961350A FI 961350 A FI961350 A FI 961350A FI 961350 L FI961350 L FI 961350L
Authority
FI
Finland
Prior art keywords
hapten
tagged peptides
tagged
peptides
Prior art date
Application number
FI961350A
Other languages
English (en)
Finnish (fi)
Other versions
FI961350A0 (sv
FI961350A7 (sv
Inventor
Eva Hoess
Christoph Seidel
Ursula-Henrike Wienhues
Elke Faatz
Urban Schmitt
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4430973A external-priority patent/DE4430973A1/de
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of FI961350A0 publication Critical patent/FI961350A0/sv
Publication of FI961350A7 publication Critical patent/FI961350A7/sv
Publication of FI961350L publication Critical patent/FI961350L/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/974Aids related test
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/82Hepatitis associated antigens and antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI961350A 1994-07-25 1995-07-24 Hapten-märkta peptider FI961350L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4426276 1994-07-25
DE4430973A DE4430973A1 (de) 1994-07-25 1994-08-31 Hapten-markierte Peptide
PCT/EP1995/002921 WO1996003423A1 (de) 1994-07-25 1995-07-24 Hapten-markierte peptide

Publications (3)

Publication Number Publication Date
FI961350A0 FI961350A0 (sv) 1996-03-25
FI961350A7 FI961350A7 (sv) 1996-03-25
FI961350L true FI961350L (sv) 1996-03-25

Family

ID=25938669

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961350A FI961350L (sv) 1994-07-25 1995-07-24 Hapten-märkta peptider

Country Status (13)

Country Link
US (1) US5804371A (sv)
EP (1) EP0723551B1 (sv)
JP (1) JP2921989B2 (sv)
CN (1) CN100478352C (sv)
AT (1) ATE214073T1 (sv)
AU (1) AU684992B2 (sv)
CA (1) CA2172144C (sv)
DE (1) DE59510092D1 (sv)
ES (1) ES2171190T3 (sv)
FI (1) FI961350L (sv)
NO (1) NO316381B1 (sv)
NZ (1) NZ291155A (sv)
WO (1) WO1996003423A1 (sv)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195753C (en) * 1994-07-25 2008-12-16 Ursula-Henrike Wienhues Determination of a specific immunoglobulin using multiple antigens
JP2000516504A (ja) * 1996-08-16 2000-12-12 ロシュ ダイアグノスティックス ゲーエムベーハー 薬剤の規則的摂取の監視システム
DE19649389A1 (de) * 1996-11-29 1998-06-04 Boehringer Mannheim Gmbh Antigenspezifischer IgM-Nachweis
WO1998040744A1 (de) 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern
DE19816550A1 (de) 1997-12-24 1999-06-24 Roche Diagnostics Gmbh Universell verwendbarer Aufbau eines Analysenelements und dessen Einsatz zur Analytbestimmung
ES2180241T3 (es) * 1998-05-06 2003-02-01 Roche Diagnostics Gmbh Eliminacion de interferencias causadas por factores reumaticos.
DE19828466A1 (de) 1998-06-26 1999-12-30 Roche Diagnostics Gmbh Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
US6503736B1 (en) 1999-11-12 2003-01-07 BIOMéRIEUX, INC. Antibodies to crosslinkers and methods for using the same
US7897404B2 (en) 2000-09-29 2011-03-01 Roche Diagnostics Operations, Inc. Conjugates of defined stoichiometry
DE10048417A1 (de) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
ATE338055T1 (de) * 2001-05-02 2006-09-15 Novo Nordisk As Verfahren zur herstellung von gallensäure
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
JP2005172694A (ja) 2003-12-12 2005-06-30 Fuji Photo Film Co Ltd タンパク質の検出方法
DE102005051978A1 (de) * 2005-10-31 2007-05-10 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Verfahren zur Bestimmung der Spaltbarkeit von Substraten
JP4975600B2 (ja) * 2007-03-16 2012-07-11 シスメックス株式会社 Hcv抗体測定用試薬キット及びhcv抗体測定方法
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
BR112013014644A2 (pt) 2011-01-03 2017-03-07 F Hoffmann - La Roche Ag composição farmacêutica e complexo
CN102323409B (zh) * 2011-01-17 2014-03-05 广东海大畜牧兽医研究院有限公司 一种病毒感染检测方法
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP3138578B1 (en) 2012-07-04 2022-01-12 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
RU2684595C2 (ru) 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты антиген-антитело
CA2872192A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2023242155A1 (en) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions and methods for the diagnosis of hiv infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135773B (en) * 1983-01-31 1985-12-04 Boots Celltech Diagnostics Enzyme inhibitor labelled immunoassay
US4767720A (en) * 1985-08-29 1988-08-30 Hsc Research Development Corporation Antidigoxin antibodies
US5087561A (en) * 1990-06-28 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists modified at position 13 by biotin
IL99077A0 (en) * 1990-08-13 1992-07-15 Merck & Co Inc New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
ATE364621T1 (de) * 1992-03-06 2007-07-15 Innogenetics Nv Hiv-peptide
DE4402756A1 (de) * 1994-01-31 1995-08-03 Boehringer Mannheim Gmbh Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine

Also Published As

Publication number Publication date
DE59510092D1 (de) 2002-04-11
NO316381B1 (no) 2004-01-19
NO961162L (no) 1996-03-21
CN100478352C (zh) 2009-04-15
EP0723551A1 (de) 1996-07-31
FI961350A0 (sv) 1996-03-25
NZ291155A (en) 1997-09-22
AU3220695A (en) 1996-02-22
CN1130910A (zh) 1996-09-11
ATE214073T1 (de) 2002-03-15
US5804371A (en) 1998-09-08
NO961162D0 (no) 1996-03-21
JP2921989B2 (ja) 1999-07-19
AU684992B2 (en) 1998-01-08
CA2172144C (en) 2001-02-06
FI961350A7 (sv) 1996-03-25
JPH09500915A (ja) 1997-01-28
ES2171190T3 (es) 2002-09-01
EP0723551B1 (de) 2002-03-06
WO1996003423A1 (de) 1996-02-08

Similar Documents

Publication Publication Date Title
FI965225A7 (sv) Nya peptider
FI961350A7 (sv) Hapten-märkta peptider
ATA166795A (de) Bis-resorcinyltriazine
ATA163695A (de) 2-hydroxyphenyltriazine
FI954147L (sv) Polypeptider
NO985680L (no) Peptidderivater
FI953302A7 (sv) Nya peptider
IS4459A (is) Ný peptíð er hafa ónæmisbreytandi áhrif
NO976058L (no) Rekombinant mistellectin
FI940109L (sv) Peptider
FI970168A7 (sv) Peptider
NO983849L (no) Peptidderivater
FI964363L (sv) Peptider
TR199701666A3 (tr) Sismanliga karsi proteinler
FI963568A7 (sv) Peptidderivat
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
NO981051D0 (no) Peptidderivater
ATA11894A (de) Stauförderbahn
BR7400683U (pt) Odontoportátil
DK1017798T3 (da) Lunasinpeptider
BR1100812A (pt) Peptìdeo
SE9504467D0 (sv) Peptide
NO20000976D0 (no) Peptider
FI1360U1 (fi) Justerbar inpassningsdetalj

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

MA Patent expired